Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis

BackgroundThe aim of this study was to investigate the relationship between absorbed dose and response of colorectal cancer liver metastases treated with [90Y]-resin microspheres and to explore possible clinical and imaging derived prognostic factors.MethodsFDG PET/CT was used to measure response of individual lesions to a measured absorbed dose, derived from post-treatment 90Y PET imaging. Predicted dose was also derived from planning [99mTc]-MAA SPECT data. Peak standardised uptake value and total lesion glycolysis (TLG) were explored as response measures, and compared to dose metrics including average dose (Davg), biologically effective dose, minimum dose to 70% of lesion volume and volume receiving at least 50 Gy. Prognostic factors examined included baseline TLG, RAS mutation status, FDG heterogeneity and dose heterogeneity. In an exploratory analysis, response and clinico-pathological variables were evaluated and compared to overall survival.ResultsSixty-three lesions were analysed from 22 patients. Poor agreement was seen between predicted and measured dose values. TLG was a superior measure of response, and all dose metrics were significant prognostic factors, with a Davg of ~50 Gy derived as the critical threshold for a significant response (>50% reduction in TLG). No significant correlation was found between baseline TLG or RAS mutation status and response. Measured dose heterogeneity was a significant prognostic factor and when combined with Davg had a positive predictive value for response >80%. In the exploratory analysis for prognostic factors of survival, low hepatic tumour burden and mean reduction in TLG >65% were independently associated with improved overall survival.ConclusionsLesions receiving an average dose greater than 50 Gy are likely to have a significant response. For lesions receiving less than 50 Gy, dose heterogeneity is a significant prognostic factor. Lesions receiving an average dose less than 20 Gy are unlikely to respond. A reduction in TLG may be associated with improved overall survival.

[1]  W. Tso,et al.  Patient dosimetry for 90Y selective internal radiation treatment based on 90Y PET imaging , 2013, Journal of applied clinical medical physics.

[2]  R. Muschel,et al.  Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. , 2000, Cancer research.

[3]  Chaosu Hu,et al.  Pretreatment 18 F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma——a retrospective study , 2015, Radiation Oncology.

[4]  S. Son,et al.  Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast , 2014, BMC Cancer.

[5]  M. Schwaiger,et al.  Textural Parameters of Tumor Heterogeneity in 18F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer , 2014, The Journal of Nuclear Medicine.

[6]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[7]  Ji-Hoon Jung,et al.  Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer , 2015, Clinical nuclear medicine.

[8]  F. Orsi,et al.  Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective , 2014, Front. Oncol..

[9]  B. Fisher,et al.  Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. , 2013, The British journal of radiology.

[10]  Akihiro Takemura,et al.  The use of positron emission tomography/computed tomography imaging in radiation therapy: a phantom study for setting internal target volume of biological target volume , 2015, Radiation oncology.

[11]  S. Walrand,et al.  Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy , 2012, EJNMMI Research.

[12]  M. D’Arienzo,et al.  Absorbed dose to lesion and clinical outcome after liver radioembolization with 90Y microspheres: a case report of PET-based dosimetry , 2013, Annals of Nuclear Medicine.

[13]  P. Bernhardt,et al.  Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy , 2014, EJNMMI Research.

[14]  Jieqing Zhu,et al.  Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition , 2014, BMC Cancer.

[15]  M. Soussan,et al.  Relationship between Tumor Heterogeneity Measured on FDG-PET/CT and Pathological Prognostic Factors in Invasive Breast Cancer , 2014, PloS one.

[16]  Michael Tapner,et al.  A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  A. Pasciak,et al.  A Microdosimetric Analysis of Absorbed Dose to Tumor as a Function of Number of Microspheres per Unit Volume in 90Y Radioembolization , 2016, The Journal of Nuclear Medicine.

[18]  V. Gebski,et al.  SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Pasciak,et al.  Treatment modification of yttrium-90 radioembolization based on quantitative positron emission tomography/CT imaging. , 2013, Journal of vascular and interventional radiology : JVIR.

[20]  D. Townsend,et al.  Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres , 2013, EJNMMI Research.

[21]  F. Banovac,et al.  Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies , 2016, Oncology reports.

[22]  S. Walrand,et al.  A Hepatic Dose-Toxicity Model Opening the Way Toward Individualized Radioembolization Planning , 2014, The Journal of Nuclear Medicine.

[23]  A. Ghodadra,et al.  Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90 , 2017, Abdominal Radiology.

[24]  Abass Alavi,et al.  Insights into the Dose–Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases , 2016, The Journal of Nuclear Medicine.

[25]  Kevin M. Brindle,et al.  Imaging Cell Death , 2014, The Journal of Nuclear Medicine.

[26]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[27]  Kathryn J Fowler,et al.  PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response , 2015, CardioVascular and Interventional Radiology.

[28]  Shelley N. Acuff,et al.  Intraprocedural yttrium-90 positron emission tomography/CT for treatment optimization of yttrium-90 radioembolization. , 2014, Journal of vascular and interventional radiology : JVIR.

[29]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[30]  M. D’Arienzo,et al.  90Y PET-based dosimetry after selective internal radiotherapy treatments , 2012, Nuclear medicine communications.

[31]  N. Habib,et al.  Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography , 2007, Nuclear medicine communications.

[32]  N. Obuchowski,et al.  Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization 90Y PET , 2014, Front. Oncol..

[33]  Y. Rolland,et al.  Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results , 2012, The Journal of Nuclear Medicine.

[34]  Marnix G E H Lam,et al.  99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.

[35]  J. Prieto,et al.  Prognostic factors and prevention of radioembolization‐induced liver disease , 2013, Hepatology.

[36]  Renaud Lhommel,et al.  Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  L. V. Elmbt,et al.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  J. Machac,et al.  Quantitative Comparison of Yttrium-90 (90 Y)-Microspheres and Technetium-99m (99m Tc)-Macroaggregated Albumin SPECT Images for Planning 90 Y Therapy of Liver Cancer , 2010, Technology in cancer research & treatment.